HomeClinical TopicsFDA approves treatment for hereditary angioedema

FDA approves treatment for hereditary angioedema

The U.S. Food and Drug Administration (FDA) has approved Firazyr (icatibant) Injection for the treatment of acute attacks of hereditary angioedema in people ages 18 years and older. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content